Literature DB >> 26485100

Allergen immunotherapy: an update on protocols of administration.

Désirée Larenas-Linnemann1.   

Abstract

PURPOSE OF REVIEW: Allergen immunotherapy (AIT) is still the only causal treatment for allergic rhinitis and asthma. However, conventional subcutaneous AIT administration schedules are time-consuming and safety issues still play a role; for sublingual AIT, the best efficacy is still investigated and for food allergy the best efficacy-safety balance is not yet completely discovered. Investigators have made progress in these fields lately. (Figure is included in full-text article.) RECENT
FINDINGS: Since January 2014, several (ultra) rush or cluster build-up phases with hypoallergic variants of extracts have been explored with success. Also, the efficacy of only preseasonal subcutaneous AIT was demonstrated for tree and grass pollen. Sublingual AIT was shown to be effective and well tolerated in allergic rhinitis and asthma with tablets and with highly concentrated liquid formulations (ragweed, house dust mite), but not cockroach. For food allergy, oral immunotherapy is promising, but close attention should be paid to the exact administration schedule, maintenance dose, and the definition of efficacy (desensitization or real tolerance, as defined by a negative challenge test at least 4 months off treatment).
SUMMARY: The practicing physician should be watchful for advances in the field of aeroallergen AIT and food oral immunotherapy, analyzing the presented information in detail and interpreting conclusions product specifically, without generalizing.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26485100     DOI: 10.1097/ACI.0000000000000220

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  4 in total

Review 1.  New Insights into Cockroach Allergens.

Authors:  Anna Pomés; Geoffrey A Mueller; Thomas A Randall; Martin D Chapman; L Karla Arruda
Journal:  Curr Allergy Asthma Rep       Date:  2017-04       Impact factor: 4.806

2.  Leukotriene A4 Hydrolase Is a Candidate Predictive Biomarker for Successful Allergen Immunotherapy.

Authors:  Ting-Ting Ma; Meng-Da Cao; Rui-Li Yu; Hai-Yun Shi; Wei-Jun Yan; Jian-Guo Liu; Chen Pan; Jinlyu Sun; Qing-Yu Wei; De-Yun Wang; Ji-Fu Wei; Xue-Yan Wang; Jin-Shu Yin
Journal:  Front Immunol       Date:  2020-11-24       Impact factor: 7.561

Review 3.  Good clinical practice recommendations in allergen immunotherapy: Position paper of the Brazilian Association of Allergy and Immunology - ASBAI.

Authors:  Fernando Monteiro Aarestrup; Ernesto Akio Taketomi; Clóvis Eduardo Santos Galvão; Elaine Gagete; Anna Caroline Nóbrega Machado Arruda; Gil Bardini Alves; Geórgia Véras de Araújo Gueiros Lira; Marcos Reis Gonçalves; Mariana Graça Couto Miziara; Sidney Souteban Maranhão Casado; Simone Valladão Curi; Veridiana Aun Rufino Pereira; Valéria Sales; Dirceu Solé; Norma de Paula Motta Rubini; Emanuel Savio Cavalcanti Sarinho
Journal:  World Allergy Organ J       Date:  2022-09-24       Impact factor: 5.516

Review 4.  How does the efficacy and safety of Oralair(®) compare to other products on the market?

Authors:  Désirée Larenas-Linnemann
Journal:  Ther Clin Risk Manag       Date:  2016-05-27       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.